DJIA 16,960.57 -123.23 -0.72%
NASDAQ 4,449.56 -22.54 -0.50%
S&P 500 1,978.34 -9.64 -0.48%
market minute promo

Durata Therapeutics (NASDAQ: DRTX)

13.70 -0.24 (-1.72%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

DRTX $13.70 -1.72%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $13.85
Previous Close $13.94
Daily Range $13.26 - $13.95
52-Week Range $7.73 - $18.17
Market Cap $365.0M
P/E Ratio -5.67
Dividend (Yield) $0.00 (0.0%)
Volume 228,171
Average Daily Volume 273,824
Current FY EPS -$2.74





Durata Therapeutics (DRTX) Description

Durata Therapeutics Inc. is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Website:

News & Commentary

3 Companies Facing FDA Approval: Chelsea, MannKind, and Durata

A video looking at upcoming FDA decisions for Chelsea Therapeutics, MannKind, and Durata Therapeutics.

Durata Therapeutics Announces US Launch of Dalvance

Commit To Buy Durata Therapeutics At $15, Earn 24.6% Annualized Using Options

Cubist Gains FDA Approval for Sivextro - Analyst Blog

Durata Therapeutics' Skin Drug Gets FDA Nod - Analyst Blog

Durata Therapeutics' Skin Drug Gets FDA Nod - Analyst Blog

Orexigen Will Run: Here's Why

Sector Update: Healthcare Stocks Higher Pre-Market; Durata Sinks 11% After Strong Rally

Sector Update: Healthcare

Benzinga's Top #PreMarket Losers

Stocks To Watch For May 27, 2014

Durata Confirms FDA Approval of DALVANCE for Skin Infections

See More DRTX News...